The Anti-Cancer Effect of Pitavastatin May Be a Drug-Specific Effect: Subgroup Analysis of the TOHO-LIP Study.

Abstract

The significance of statin treatment for the reduction of cardiovascular (CV) disease has been reported, whereas other reports have also described anti-cancer properties associated with the class effect of statins. However, the differences in anti-cancer effect of various types of statins have rarely been examined. Pitavastatin is a statin with a different chemical structure and pharmacokinetics from other statins, and the mechanism of the specific anti-cancer effect of pitavastatin has been reported in in vivo therapeutic models. We previously revealed that pitavastatin therapy was superior to atorvastatin therapy in the prevention of CV events, despite similar LDL-cholesterol-lowering effect in the TOHO Lipid Intervention Trial Using Pitavastatin (TOHO-LIP). Furthermore, in subgroup analysis of the TOHO-LIP study, cumulative 240-week incidence of new cancer cases tended to be lower in the pitavastatin group compared to the atorvastatin group [0.32% (1/312) vs 1.94% (6/310), log-rank P=0.051]. This finding might reveal the superiority of pitavastatin to prevent carcinogenesis. The molecular mechanism by which pitavastatin suppresses the incidence of any-organ cancer is gradually elucidated, and new combination of cancer treatments with pitavastatin will be developed in the future to further enhance the anti-cancer activity and reduce the side effects.

• Authors: Daiji Nagayama, Atsuhito Saiki, Kohji Shirai
• Journal: Vascular health and risk management (Vasc Health Risk Manag) Vol. 17 Pg. 169-173 ( 2021) ISSN: 1178-2048 [Electronic] New Zealand
• PMID: 33953560 (Publication Type: Journal Article)
• Copyright: © 2021 Nagayama et al.

Chemical References

• Anticarcinogenic Agents
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Quinolines
• pitavastatin

Topics

• Animals
• Anticarcinogenic Agents (adverse effects, therapeutic use)
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (adverse effects, therapeutic use)
• Incidence
• Neoplasms (epidemiology, prevention & control)
• Protective Factors
• Quinolines (adverse effects, therapeutic use)
• Randomized Controlled Trials as Topic
• Risk Assessment
• Risk Factors